Acute myeloid leukemia induction chemotherapy — 7 days continuous cytarabine + 3 days concurrent anthracycline, eliminating leukemic blasts through DNA-directed cytotoxicity
For over four decades, the combination of 7 days of continuous-infusion cytarabine with 3 days of concurrent anthracycline has remained the standard induction regimen for fit patients with newly diagnosed acute myeloid leukemia. Despite the arrival of targeted agents and novel combinations, "7+3" persists as the reference backbone against which nearly every modern AML trial is measured.
The "7+3" name describes the two overlapping infusion schedules that make up induction:
Cytarabine (cytosine arabinoside, ara-C): • Administered as a continuous intravenous infusion over 24 hours per day • Given for 7 consecutive days (days 1–7 of the cycle) • Standard dose: 100–200 mg/m²/day; the drug bathes rapidly dividing cells throughout the entire week • Continuous exposure matters because ara-C is most active against cells actively synthesizing DNA (S-phase specific) — a longer exposure window catches more cells as they cycle through S-phase
Anthracycline (daunorubicin, or idarubicin as an alternative): • Administered as a short IV infusion or push, once daily • Given for the first 3 days only (days 1–3), overlapping with the start of the cytarabine infusion • Daunorubicin dose: historically 45 mg/m²/day, but modern trials (e.g., the ECOG-ACRIN E1900 study) established 90 mg/m²/day for younger/fit patients as superior to 45 mg/m²/day • Idarubicin, when substituted, is typically dosed at 12 mg/m²/day for 3 days
Why concurrent, front-loaded dosing: • Combining both agents at the start of the cycle maximizes early cytotoxic pressure on the leukemic clone while the marrow still has some reserve • The anthracycline's short, intense exposure targets topoisomerase II-dependent processes, while cytarabine's week-long presence maximizes S-phase capture • After day 7, no further chemotherapy is given — the regimen then transitions into a purely observational and supportive phase while the marrow responds
"7+3" is generally reserved for patients considered fit for intensive induction — typically younger patients or those with good performance status and preserved organ function, since it produces predictable, severe myelosuppression that requires inpatient monitoring and supportive care infrastructure.
Common variants and additions: • "High-dose" cytarabine substitutions exist for consolidation but are not used in the standard induction backbone itself • Addition of a third agent — for example, midostaurin for FLT3-mutated AML, or gemtuzumab ozogamicin for CD33-positive disease — layered onto the "7+3" backbone in molecularly-defined subgroups • CPX-351 (liposomal daunorubicin + cytarabine in a fixed 1:5 molar ratio) is a reformulated delivery variant used preferentially in therapy-related AML and AML with myelodysplasia-related changes • Older or unfit patients are more often directed toward lower-intensity approaches (e.g., venetoclax + hypomethylating agent) rather than classic "7+3"
The therapeutic logic of "7+3" rests on combining two mechanistically distinct DNA-directed cytotoxins. Cytarabine sabotages DNA replication itself, while the anthracycline poisons the topoisomerase II enzyme required to safely unwind and reseal DNA during replication and transcription. Used together, they attack the leukemic blast population — cells characterized by high proliferative rate — from two complementary angles simultaneously.
Cytarabine (ara-C) is a deoxycytidine analog that hijacks the cell's own replication machinery:
• Cellular uptake and activation: ara-C enters cells via nucleoside transporters and is sequentially phosphorylated by deoxycytidine kinase and other kinases to its active triphosphate form, ara-CTP • Incorporation into DNA: ara-CTP competes with the natural nucleotide dCTP for incorporation by DNA polymerase α during replication • Chain termination: once incorporated, ara-C's altered sugar geometry (arabinose instead of ribose) blocks the 3'-5' phosphodiester bond formation needed to extend the growing DNA strand — replication stalls • Because this mechanism requires active DNA synthesis, ara-C selectively damages cells in S-phase — precisely the rapidly dividing leukemic blast population — while relatively sparing quiescent, non-cycling cells • The 7-day continuous infusion schedule exists specifically to maximize the chance that every blast cell passes through S-phase at some point during the drug exposure window, since leukemic cells cycle asynchronously
Daunorubicin (or idarubicin) contributes a second, mechanistically independent form of DNA damage:
• DNA intercalation: the planar anthracycline ring structure inserts itself between adjacent base pairs in the DNA double helix, distorting its structure and interfering with both replication and transcription • Topoisomerase II poisoning: topoisomerase II normally makes transient double-strand breaks to relieve torsional strain during replication, then reseals them. Anthracyclines trap the enzyme-DNA complex in its cleaved state, converting a normally transient break into a persistent, lethal double-strand DNA break • Free radical generation: anthracyclines also undergo redox cycling, generating reactive oxygen species that cause additional oxidative DNA damage — this mechanism also underlies their dose-limiting cardiotoxicity • Because topoisomerase II activity is required broadly during proliferation (not restricted to a single phase), anthracyclines add cytotoxic pressure across more of the cell cycle than cytarabine alone
Combined effect: the accumulated DNA damage from both mechanisms overwhelms the DNA-damage response and repair capacity of leukemic blasts, triggering p53-mediated (or p53-independent, in TP53-mutated disease) apoptotic cell death. Normal hematopoietic stem and progenitor cells are also proliferating, however — which is why induction inevitably produces a period of marrow aplasia alongside leukemic clearance.
Because "7+3" cannot fully distinguish leukemic blasts from normal hematopoietic progenitors, induction chemotherapy intentionally drives the bone marrow into a period of profound aplasia. This is not a complication to be avoided — it is an expected, necessary consequence of achieving adequate leukemic cell kill, and the several weeks that follow require intensive, protocolized supportive care.
Both leukemic blasts and normal marrow progenitors are dividing rapidly at the time of induction, so cytarabine and the anthracycline cannot selectively spare healthy hematopoiesis. The result is a global marrow aplasia — profound pancytopenia — that typically begins around 7–10 days after the start of chemotherapy and persists for roughly two to four weeks while both the leukemic clone (hopefully) and normal stem/progenitor cells attempt to repopulate the marrow space.
During this window, patients characteristically experience: • Severe neutropenia (ANC often <100–500/µL), placing them at very high risk of bacterial and fungal infection • Thrombocytopenia, with bleeding risk rising sharply below ~10,000–20,000 platelets/µL • Anemia requiring red cell transfusion support • Mucositis and generalized cytopenia-related fatigue and malaise
This period is the most medically vulnerable phase of the entire induction course, and essentially all AML induction is delivered as an inpatient admission specifically because of the intensity of monitoring and rapid-response supportive care it demands.
A structured supportive care bundle is applied throughout the aplastic window:
• Infection prophylaxis: antibacterial, antifungal, and antiviral prophylaxis (regimens vary by institution) initiated as neutropenia develops • Febrile neutropenia protocol: any fever in a neutropenic patient triggers immediate empiric broad-spectrum antibiotics after blood cultures, without waiting for a source to be identified • Transfusion support: platelet transfusions to maintain counts above institutional bleeding-risk thresholds; packed red cell transfusions for symptomatic or significant anemia • Growth factor support: myeloid growth factors (e.g., G-CSF) are used selectively in some protocols to shorten neutropenic duration, though practice varies • Close monitoring: daily complete blood counts, vigilant assessment for signs of infection or bleeding, and readiness to escalate to intensive care if sepsis or hemorrhagic complications develop
The intensity of supportive care required is not constant — it rises sharply as counts fall through the first two weeks, peaks during the deepest nadir, and gradually tapers as marrow recovery begins, typically in the third to fourth week of the induction course.
The aplastic period is the price of efficacy: a marrow that is not driven into aplasia has usually not received an adequately cytotoxic dose to clear the leukemic clone. Supportive care infrastructure — not dose reduction — is the primary tool used to make this necessary toxicity survivable.
Roughly two weeks into the induction course, while the patient is still deep in the aplastic window, many protocols call for an interim bone marrow biopsy. This "day 14" assessment is not used to declare remission — counts have not yet recovered — but rather to gauge how effectively the leukemic blast population has been cleared and whether additional or reinforced treatment may be needed.
The day 14 marrow sample is examined for two related features:
• Overall cellularity: an adequately treated marrow at this point should already be markedly hypocellular, reflecting the expected chemotherapy-induced aplasia described in the previous stage. A marrow that remains densely cellular at day 14 may suggest inadequate cytotoxic effect. • Residual blast percentage: the proportion of blast cells remaining in the sample is the key quantitative readout. A low residual blast percentage (commonly cited around <5%, in the setting of an appropriately hypocellular marrow) is reassuring evidence that the leukemic clone has been substantially cleared and that normal hematopoietic recovery is likely to follow. • A higher residual blast percentage — particularly with preserved marrow cellularity — raises concern that the induction dose has not adequately eliminated the leukemic population, and that the marrow may re-expand with residual disease rather than normal hematopoiesis.
Because counts have not yet recovered at this point, this is explicitly an interim, early-response checkpoint — it complements, but does not replace, the definitive remission assessment performed later, once blood counts have recovered.
The day 14 result feeds directly into a treatment decision:
• Good early response (low residual blasts, hypocellular marrow): the clinical team generally continues to observe and await count recovery, proceeding toward the definitive post-recovery remission assessment without additional chemotherapy. • Residual disease (elevated blast percentage, especially with retained cellularity): this may prompt consideration of a second induction course — "reinduction" — often with the same or an intensified/alternative regimen, in an effort to achieve adequate clearance before the marrow has a chance to repopulate with leukemia rather than normal cells.
Practice varies by institution and protocol regarding the exact blast percentage threshold and the routine use of day 14 biopsies at all — some centers reserve marrow assessment for later, count-recovery time points, relying instead on clinical trajectory during the first two weeks. Where used, however, the day 14 checkpoint provides valuable early information at a point when intervention can still meaningfully change the treatment course.
The definitive assessment of induction success occurs after blood counts have recovered, typically several weeks after chemotherapy began. A bone marrow evaluation at this point determines whether complete remission has been achieved — and that determination is the fork in the road that decides whether the patient proceeds to consolidation therapy or requires reinduction or an alternative treatment strategy.
Complete remission after induction is a composite clinical and laboratory determination, generally requiring all of the following once counts have recovered:
• Bone marrow blasts below 5% on morphologic examination • Absence of circulating blasts and no extramedullary (outside the marrow) leukemic disease • Recovery of peripheral blood counts: absolute neutrophil count generally above 1,000/µL and platelet count above 100,000/µL • Increasingly, measurable (minimal) residual disease (MRD) testing — using flow cytometry or molecular methods — is layered onto morphologic CR to detect submicroscopic leukemic burden that predicts higher relapse risk even in patients who otherwise meet standard CR criteria
This full assessment, unlike the interim day 14 checkpoint, is what actually defines induction success and triggers the transition to the next phase of treatment.
The remission assessment result determines the treatment path:
If complete remission is achieved: • Patients move to consolidation therapy, intended to eliminate residual leukemic cells below the threshold of morphologic detection and reduce relapse risk • Consolidation options range from repeated cycles of high-dose cytarabine to allogeneic hematopoietic stem cell transplantation, chosen based on cytogenetic/molecular risk stratification, MRD status, patient fitness, and donor availability
If induction fails to achieve complete remission: • Reinduction with the same or an alternative intensive regimen may be attempted • Salvage strategies — alternative chemotherapy combinations, targeted agents matched to molecular alterations, or early referral for allogeneic transplant/clinical trial — are considered for refractory disease • Induction failure carries a materially worse prognosis, making the choice of salvage strategy and the speed of the decision clinically important
The entire "7+3" induction sequence — regimen delivery, the aplastic window, the day 14 checkpoint, and the final remission assessment — exists to answer one question as efficiently and safely as possible: has the leukemic clone been eliminated enough for normal hematopoiesis, and ultimately consolidation therapy, to take over.